PT1243262E - Nova utilizacao de uma classe de compostos peptideos para o tratamento da dor inflamatoria nao neuropatica - Google Patents

Nova utilizacao de uma classe de compostos peptideos para o tratamento da dor inflamatoria nao neuropatica

Info

Publication number: PT1243262E
Authority: PT; Portugal
Prior art keywords: pain; class; inflammatory pain; treatment; inflammatory
Prior art date: 2001-03-20

Application number

PT01106891T

Other languages

English (en)

Inventor

Norma Dr Selve

Original Assignee

Sanol Arznei Schwarz Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-20

Filing date

2001-03-20

Publication date

2006-10-31

2001-03-20 Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh

2006-10-31 Publication of PT1243262E publication Critical patent/PT1243262E/pt

Links

206010065390 Inflammatory pain Diseases 0.000 title abstract 3
150000001875 compounds Chemical class 0.000 title abstract 3
108090000765 processed proteins & peptides Proteins 0.000 title 1
208000002193 Pain Diseases 0.000 abstract 5
229940035676 analgesics Drugs 0.000 abstract 2
239000000730 antalgic agent Substances 0.000 abstract 2
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 2
208000000094 Chronic Pain Diseases 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
230000001154 acute effect Effects 0.000 abstract 1
208000005298 acute pain Diseases 0.000 abstract 1
230000003502 anti-nociceptive effect Effects 0.000 abstract 1
230000001684 chronic effect Effects 0.000 abstract 1
230000002757 inflammatory effect Effects 0.000 abstract 1
230000002981 neuropathic effect Effects 0.000 abstract 1
229940005483 opioid analgesics Drugs 0.000 abstract 1
230000003349 osteoarthritic effect Effects 0.000 abstract 1
206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
208000024891 symptom Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

PT01106891T 2001-03-20 2001-03-20 Nova utilizacao de uma classe de compostos peptideos para o tratamento da dor inflamatoria nao neuropatica PT1243262E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP01106891A EP1243262B1 (en)	2001-03-20	2001-03-20	Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain

Publications (1)

Publication Number	Publication Date
PT1243262E true PT1243262E (pt)	2006-10-31

Family

ID=8176844

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT01106891T PT1243262E (pt)	2001-03-20	2001-03-20	Nova utilizacao de uma classe de compostos peptideos para o tratamento da dor inflamatoria nao neuropatica
PT02727437T PT1373300E (pt)	2001-03-20	2002-03-19	Nova utilização de uma classe peptídica de compostos no tratamento de dor inflamatória não neuropática

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT02727437T PT1373300E (pt)	2001-03-20	2002-03-19	Nova utilização de uma classe peptídica de compostos no tratamento de dor inflamatória não neuropática

Country Status (31)

Country	Link
US (3)	US6803481B2 (pt)
EP (2)	EP1243262B1 (pt)
JP (1)	JP4955906B2 (pt)
KR (1)	KR100773100B1 (pt)
CN (2)	CN101332292B (pt)
AT (2)	ATE327744T1 (pt)
AU (1)	AU2002257681C1 (pt)
BR (1)	BR0205823A (pt)
CA (1)	CA2419397C (pt)
CY (3)	CY1105533T1 (pt)
CZ (1)	CZ20032763A3 (pt)
DE (3)	DE60120104T2 (pt)
DK (2)	DK1243262T3 (pt)
EA (1)	EA007532B1 (pt)
ES (2)	ES2262567T3 (pt)
FR (1)	FR09C0041I2 (pt)
HK (1)	HK1058368A1 (pt)
HU (1)	HUP0303600A3 (pt)
IL (2)	IL154087A0 (pt)
LU (1)	LU91590I2 (pt)
MX (1)	MXPA03008467A (pt)
NL (1)	NL300399I1 (pt)
NO (1)	NO20033629D0 (pt)
NZ (1)	NZ523865A (pt)
PL (1)	PL216213B1 (pt)
PT (2)	PT1243262E (pt)
SI (2)	SI21170A (pt)
SK (1)	SK287539B6 (pt)
UA (1)	UA82645C2 (pt)
WO (1)	WO2002074784A2 (pt)
ZA (1)	ZA200300858B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2740815C (en) *	2000-08-25	2014-03-18	Research Corporation Technologies, Inc.	New uses for amino acid anticonvulsants
DK1243262T3 (da) *	2001-03-20	2006-10-02	Sanol Arznei Schwarz Gmbh	Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter
EP1243263B1 (en) *	2001-03-21	2002-11-27	Schwarz Pharma Ag	Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain
ATE428413T1 (de) *	2003-12-02	2009-05-15	Sanol Arznei Schwarz Gmbh	Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
US20100256179A1 (en) *	2004-03-26	2010-10-07	Ucb Pharma Gmbh	Combination therapy for pain in painful diabetic neuropathy
US20070042969A1 (en) *	2004-03-26	2007-02-22	Srz Properties, Inc.	Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (en) *	2004-03-26	2005-09-28	Schwarz Pharma Ag	Novel use of peptide compounds for treating pain in painful diabetic neuropathy
NZ550482A (en) *	2004-04-16	2010-08-27	Sanol Arznei Schwarz Gmbh	Use of peptidic compounds for the prophylaxis and treatment of chronic headache
CN100562312C (zh) *	2004-05-18	2009-11-25	舒沃茨药物股份公司	肽化合物用于治疗运动障碍的新用途
EP1604654A1 (en) *	2004-05-18	2005-12-14	Schwarz Pharma Ag	Novel use of peptide compounds for treating dyskinesia
EP1604656A1 (en)	2004-06-09	2005-12-14	Schwarz Pharma Ag	Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
EP1604655A1 (en) *	2004-06-09	2005-12-14	Schwarz Pharma Ag	Novel use of peptide compounds for treating pain in trigeminal neuralgia
US7427601B2 (en)	2004-06-24	2008-09-23	Schwarz Pharma Ag	Method for treating tremor
CA2573125A1 (en) *	2004-08-27	2006-03-02	Schwarz Pharma Ag	Novel use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain
EP1642889A1 (en) *	2004-10-02	2006-04-05	Schwarz Pharma Ag	Improved synthesis scheme for lacosamide
CA2595330A1 (en)	2005-01-28	2006-08-03	Schwarz Pharma Ag	Spm 927 for add-on therapy of schizophrenia
US20060252749A1 (en) *	2005-01-28	2006-11-09	Srz Properties, Inc.	Lacosamide for add-on therapy of psychosis
US20070048372A1 (en) *	2005-08-18	2007-03-01	Srz Properties, Inc.	Method for treating non-inflammatory osteoarthritic pain
EP1754476A1 (en) *	2005-08-18	2007-02-21	Schwarz Pharma Ag	Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070043120A1 (en) *	2005-08-18	2007-02-22	Bettina Beyreuther	Therapeutic combination for painful medical conditions
GB0523550D0 (en)	2005-11-18	2005-12-28	Hunter Fleming Ltd	Therapeutic uses of steroidal compounds
WO2007141018A1 (en) *	2006-06-08	2007-12-13	Schwarz Pharma Ag	Therapeutic combination for painful medical conditions
EP1873527A1 (en) *	2006-06-30	2008-01-02	Schwarz Pharma Ag	Method for identifying CRMP modulators
CN101466390B (zh) *	2006-06-15	2014-03-12	优时比制药有限公司	用于治疗难治性癫痫持续状态的肽类化合物
EP1920780A1 (en) *	2006-10-12	2008-05-14	Schwarz Pharma Ag	Peptide compounds for the treatment of hyperexcitability disorders
ES2450070T5 (es)	2006-06-15	2018-05-08	Ucb Pharma Gmbh	Composición farmacéutica que comprende lacosamida y levetiracetam con efecto anticonvulsionante sinérgico
CA2774569A1 (en) *	2009-09-23	2011-03-31	The University Of North Carolina At Chapel Hill	Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents
NZ610701A (en)	2010-12-02	2015-06-26	Ucb Pharma Gmbh	Once daily formulation of lacosamide
EP2468261A1 (en)	2010-12-02	2012-06-27	UCB Pharma GmbH	Formulation of lacosamide
GB2524689B (en)	2011-05-20	2016-01-27	Gw Pharma Ltd	Cannabinoids for use in the treatment of neuropathic pain

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2937698A1 (de)	1979-09-18	1981-04-02	A. Nattermann & Cie GmbH, 5000 Köln	N-propionylsarcosinanilide, deren herstellungsverfahren und arzneimittel auf deren basis
FR2480747A1 (fr)	1980-04-17	1981-10-23	Roques Bernard	Derives d'acides amines et leur application therapeutique
US4533657A (en)	1981-07-24	1985-08-06	Sterling Drug Inc.	Analgesic dipeptide amides and method of use and composition thereof
FR2518088B1 (fr)	1981-12-16	1987-11-27	Roques Bernard	Nouveaux derives d'aminoacides, et leur application therapeutique
US4510082A (en)	1983-03-07	1985-04-09	Eli Lilly And Company	Pharmacologically active peptides
JPH0680079B2 (ja)	1984-11-09	1994-10-12	エーザイ株式会社	ポリペプチド
US5654301A (en) *	1985-02-15	1997-08-05	Research Corporation Technologies, Inc.	Amino acid derivative anticonvulsant
US5378729A (en) *	1985-02-15	1995-01-03	Research Corporation Technologies, Inc.	Amino acid derivative anticonvulsant
GB9103454D0 (en)	1991-02-19	1991-04-03	Pfizer Ltd	Therapeutic agents
US5656267A (en) *	1991-08-22	1997-08-12	Sagen; Jacqueline	Implantable cells that alleviate chronic pain in humans
TW217417B (pt)	1991-12-04	1993-12-11	Manyu Seiyaku Kk
US5278729A (en) *	1992-04-10	1994-01-11	Magnavox Electronic Systems Company	Compact rotatable electrical device
US5585358A (en)	1993-07-06	1996-12-17	Yissum Research Development Corporation Of The Hebrew University Of Jerusalem	Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
DE69512891T2 (de) *	1994-01-22	2000-02-24	British Biotech Pharm	Metalloproteinaseinhibitoren
IL112759A0 (en) *	1994-02-25	1995-05-26	Khepri Pharmaceuticals Inc	Novel cysteine protease inhibitors
GB9504854D0 (en)	1994-03-31	1995-04-26	Zeneca Ltd	Nitrogen derivatives
US5536853A (en)	1994-04-11	1996-07-16	Chiron Corporation	Opiate receptor ligands
MY113062A (en) *	1994-05-10	2001-11-30	The Wellcome Foundation Ltd	Amide derivatives and their therapeutic use
US5508266A (en)	1994-06-22	1996-04-16	Ciba-Geigy Corporation	Gem-disubstituted amino acid derivatives
WO1996011209A1 (en)	1994-10-05	1996-04-18	Chiroscience Limited	Peptidyl compounds and their therapeutic use as inhibitors of metalloproteases
DE19533023B4 (de)	1994-10-14	2007-05-16	Basf Ag	Neue Carbonsäurederivate, ihre Herstellung und Verwendung
US5780589A (en)	1994-11-30	1998-07-14	The United States Of America As Represented By The Department Of Health And Human Services	Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof
US5760038A (en)	1995-02-06	1998-06-02	Bristol-Myers Squibb Company	Substituted biphenyl sulfonamide endothelin antagonists
US5849737A (en)	1995-04-14	1998-12-15	The Regents Of The University Of California	Compositions and methods for treating pain
WO1997003677A1 (en)	1995-07-24	1997-02-06	Trustees Of Boston University	Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
US6114390A (en)	1995-11-30	2000-09-05	Karl Thomae Gmbh	Amino acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
US6037324A (en)	1996-01-04	2000-03-14	Leukosite, Inc.	Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
GB9601724D0 (en)	1996-01-29	1996-03-27	Merck Sharp & Dohme	Therapeutic agents
US5773475A (en) *	1997-03-17	1998-06-30	Research Corporation Technologies, Inc.	Anticonvulsant enantiomeric amino acid derivatives
DE19614533A1 (de)	1996-04-12	1997-10-16	Basf Ag	Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung
DE19614534A1 (de)	1996-04-12	1997-10-16	Basf Ag	Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19614542A1 (de)	1996-04-12	1997-10-16	Basf Ag	Neue Carbonsäurederivate, ihre Herstellung und Verwendung
US6277825B1 (en) *	1996-07-22	2001-08-21	University Of Utah Research Foundation	Use of conantokins for treating pain
US6001876A (en)	1996-07-24	1999-12-14	Warner-Lambert Company	Isobutylgaba and its derivatives for the treatment of pain
US6589994B1 (en)	1996-08-30	2003-07-08	Nps Pharmaceuticals, Inc.	Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
US6126939A (en)	1996-09-03	2000-10-03	Yeda Research And Development Co. Ltd.	Anti-inflammatory dipeptide and pharmaceutical composition thereof
DE19636046A1 (de)	1996-09-05	1998-03-12	Basf Ag	Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
US6034136A (en) *	1997-03-20	2000-03-07	Novartis Ag	Certain cyclic thio substituted acylaminoacid amide derivatives
US5866585A (en)	1997-05-22	1999-02-02	Synchroneuron, Llc	Methods of treating tardive dyskinesia using NMDA receptor antagonists
AU7937298A (en)	1997-07-08	1999-02-08	Ono Pharmaceutical Co. Ltd.	Amino acid derivatives
US6737408B1 (en)	1997-08-07	2004-05-18	University Of Cincinnati	Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
AU7696098A (en) *	1997-08-11	1999-03-01	Algos Pharmaceutical Corporation	Substance p inhibitors in combination with nmda-blockers for treating pain
DE19743143A1 (de)	1997-09-30	1999-04-01	Knoll Ag	Pharmazeutische Kombinationspräparate
WO1999023078A2 (de)	1997-10-31	1999-05-14	Basf Aktiengesellschaft	Neue carbonsäurederivate, die amidseitenketten tragen, ihre herstellung und verwendung als endothelin-rezeptorantagonisten
US6028102A (en) *	1998-02-24	2000-02-22	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Anticonvulsant drugs and pharmaceutical compositions thereof
HUP0201402A3 (en)	1999-09-03	2003-12-29	Actelion Pharmaceuticals Ltd	Bis-sulfonamides, process for their preparation and pharmaceutical compositions containing them
SE0001373D0 (sv) *	2000-04-13	2000-04-13	Karolinska Innovations Ab	NPY Y1 receptor agonists and antagonists
CA2418455A1 (en)	2000-08-17	2002-02-21	Teva Pharmaceutical Industries, Ltd.	Valproic acid derivatives for the treatment of pain
CA2740815C (en)	2000-08-25	2014-03-18	Research Corporation Technologies, Inc.	New uses for amino acid anticonvulsants
US7112612B2 (en)	2000-11-21	2006-09-26	Ucb S.A.	N-alkylated GABA compounds, processes for their preparation and their use as medicaments
DK1243262T3 (da) *	2001-03-20	2006-10-02	Sanol Arznei Schwarz Gmbh	Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter
EP1243263B1 (en)	2001-03-21	2002-11-27	Schwarz Pharma Ag	Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain
KR20040016844A (ko)	2001-03-27	2004-02-25	액테리온 파마슈티칼 리미티드	유로텐신 ⅱ 수용체 길항제인1,2,3,4-테트라하이드로이소퀴놀린 유도체
PL367262A1 (en)	2001-04-26	2005-02-21	Bristol-Myers Squibb Company	A pharmaceutical tablet having a high api content
ITMI20011308A1 (it) *	2001-06-21	2002-12-21	Nicox Sa	Farmaci per il dolore cronico
US7183259B2 (en)	2002-05-17	2007-02-27	Xenoport	Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
ATE361289T1 (de)	2002-08-05	2007-05-15	Lilly Co Eli	Piperazinsubstituierte arylbenzodiazepine
EP1575919A1 (en)	2002-11-11	2005-09-21	Bayer HealthCare AG	Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
DE60318749T2 (de)	2002-11-18	2009-01-22	Bioprospecting Nb Inc.	Paralytisches peptid von der spitzmaus sowie dessen nutzung in der therapie von neuromuskulären krankheiten
US7687080B2 (en)	2002-11-25	2010-03-30	Taraxos Inc.	Treatment of neuropathy
BR0317392A (pt)	2002-12-19	2005-12-20	Pharmacia Corp	Formulação não-higroscópica incluindo uma droga higroscópica
EP1589959A2 (en)	2003-01-30	2005-11-02	Dynogen Pharmaceuticals Inc.	Methods of treating lower urinary tract disorders using sodium channel modulators
EP1596844A2 (en)	2003-01-30	2005-11-23	Dynogen Pharmaceuticals Inc.	Use of sodium channel modulators for treating gastrointestinal tract disorders
US20040265375A1 (en)	2003-04-16	2004-12-30	Platteeuw Johannes J.	Orally disintegrating tablets
US20040266743A1 (en)	2003-05-09	2004-12-30	Pharmacia Corporation	Combination of an aldosterone receptor antagonist and a renin inhibitor
US7320675B2 (en)	2003-08-21	2008-01-22	Cardiac Pacemakers, Inc.	Method and apparatus for modulating cellular metabolism during post-ischemia or heart failure
EP1537862A1 (en)	2003-12-02	2005-06-08	Schwarz Pharma Ag	Novel use of peptide compounds for treating central neuropathic pain
ATE428413T1 (de)	2003-12-02	2009-05-15	Sanol Arznei Schwarz Gmbh	Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
US20060009384A1 (en)	2003-12-05	2006-01-12	David Rudd	Novel use of peptide compounds for treating status epilepticus or related conditions
EP1541138A1 (en)	2003-12-05	2005-06-15	Schwarz Pharma Ag	Novel use of peptide compounds for treating status epilepticus or related conditions
US20070042969A1 (en)	2004-03-26	2007-02-22	Srz Properties, Inc.	Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (en)	2004-03-26	2005-09-28	Schwarz Pharma Ag	Novel use of peptide compounds for treating pain in painful diabetic neuropathy
US20050227961A1 (en)	2004-04-08	2005-10-13	Vela Pharmaceuticals, Inc.	Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
NZ550482A (en)	2004-04-16	2010-08-27	Sanol Arznei Schwarz Gmbh	Use of peptidic compounds for the prophylaxis and treatment of chronic headache
EP1604654A1 (en)	2004-05-18	2005-12-14	Schwarz Pharma Ag	Novel use of peptide compounds for treating dyskinesia
EP1604655A1 (en)	2004-06-09	2005-12-14	Schwarz Pharma Ag	Novel use of peptide compounds for treating pain in trigeminal neuralgia
EP1604656A1 (en)	2004-06-09	2005-12-14	Schwarz Pharma Ag	Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
US7427601B2 (en)	2004-06-24	2008-09-23	Schwarz Pharma Ag	Method for treating tremor
CA2573125A1 (en)	2004-08-27	2006-03-02	Schwarz Pharma Ag	Novel use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain
EP1642889A1 (en)	2004-10-02	2006-04-05	Schwarz Pharma Ag	Improved synthesis scheme for lacosamide
US20060252749A1 (en)	2005-01-28	2006-11-09	Srz Properties, Inc.	Lacosamide for add-on therapy of psychosis
EP1688137A1 (en)	2005-01-28	2006-08-09	Schwarz Pharma Ag	SPM 927 for add-on therapy of schizophrenia
US20070043120A1 (en)	2005-08-18	2007-02-22	Bettina Beyreuther	Therapeutic combination for painful medical conditions
EP1754476A1 (en)	2005-08-18	2007-02-21	Schwarz Pharma Ag	Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070048372A1 (en)	2005-08-18	2007-03-01	Srz Properties, Inc.	Method for treating non-inflammatory osteoarthritic pain

2001
- 2001-03-20 DK DK01106891T patent/DK1243262T3/da active
- 2001-03-20 EP EP01106891A patent/EP1243262B1/en not_active Expired - Lifetime
- 2001-03-20 ES ES01106891T patent/ES2262567T3/es not_active Expired - Lifetime
- 2001-03-20 AT AT01106891T patent/ATE327744T1/de not_active IP Right Cessation
- 2001-03-20 DE DE60120104T patent/DE60120104T2/de not_active Expired - Fee Related
- 2001-03-20 PT PT01106891T patent/PT1243262E/pt unknown
2002
- 2002-03-19 BR BR0205823-5A patent/BR0205823A/pt not_active Application Discontinuation
- 2002-03-19 ES ES02727437T patent/ES2326627T3/es not_active Expired - Lifetime
- 2002-03-19 PL PL362985A patent/PL216213B1/pl not_active IP Right Cessation
- 2002-03-19 DK DK02727437T patent/DK1373300T3/da active
- 2002-03-19 US US10/344,885 patent/US6803481B2/en not_active Expired - Fee Related
- 2002-03-19 DE DE122009000053C patent/DE122009000053I1/de active Pending
- 2002-03-19 AT AT02727437T patent/ATE431833T1/de active
- 2002-03-19 IL IL15408702A patent/IL154087A0/xx unknown
- 2002-03-19 CZ CZ20032763A patent/CZ20032763A3/cs unknown
- 2002-03-19 UA UA2003109401A patent/UA82645C2/uk unknown
- 2002-03-19 EP EP02727437A patent/EP1373300B1/en not_active Expired - Lifetime
- 2002-03-19 WO PCT/EP2002/003034 patent/WO2002074784A2/en active IP Right Grant
- 2002-03-19 PT PT02727437T patent/PT1373300E/pt unknown
- 2002-03-19 CN CN2008101283801A patent/CN101332292B/zh not_active Expired - Fee Related
- 2002-03-19 AU AU2002257681A patent/AU2002257681C1/en not_active Ceased
- 2002-03-19 SI SI200220008A patent/SI21170A/sl not_active IP Right Cessation
- 2002-03-19 SK SK1283-2003A patent/SK287539B6/sk not_active IP Right Cessation
- 2002-03-19 DE DE60232407T patent/DE60232407D1/de not_active Expired - Lifetime
- 2002-03-19 CA CA002419397A patent/CA2419397C/en not_active Expired - Fee Related
- 2002-03-19 EA EA200300932A patent/EA007532B1/ru not_active IP Right Cessation
- 2002-03-19 NZ NZ523865A patent/NZ523865A/xx unknown
- 2002-03-19 SI SI200230842T patent/SI1373300T1/sl unknown
- 2002-03-19 MX MXPA03008467A patent/MXPA03008467A/es active IP Right Grant
- 2002-03-19 JP JP2002573793A patent/JP4955906B2/ja not_active Expired - Fee Related
- 2002-03-19 KR KR1020037002844A patent/KR100773100B1/ko not_active IP Right Cessation
- 2002-03-19 CN CNB028067614A patent/CN100415225C/zh not_active Expired - Fee Related
- 2002-03-19 HU HU0303600A patent/HUP0303600A3/hu unknown
2003
- 2003-01-22 IL IL154087A patent/IL154087A/en not_active IP Right Cessation
- 2003-01-31 ZA ZA200300858A patent/ZA200300858B/xx unknown
- 2003-08-15 NO NO20033629A patent/NO20033629D0/no not_active Application Discontinuation
2004
- 2004-02-16 HK HK04101107.4A patent/HK1058368A1/xx not_active IP Right Cessation
- 2004-10-08 US US10/962,240 patent/US20050085423A1/en not_active Abandoned
2006
- 2006-08-21 US US11/507,110 patent/US8053476B2/en not_active Expired - Fee Related
- 2006-08-30 CY CY20061101223T patent/CY1105533T1/el unknown
2009
- 2009-08-05 LU LU91590C patent/LU91590I2/fr unknown
- 2009-08-06 NL NL300399C patent/NL300399I1/nl unknown
- 2009-08-12 CY CY20091100865T patent/CY1109308T1/el unknown
- 2009-09-07 FR FR09C0041C patent/FR09C0041I2/fr active Active
- 2009-09-16 CY CY2009013C patent/CY2009013I2/el unknown

Also Published As

Publication number	Publication date
EP1243262A1 (en)	2002-09-25
DK1373300T3 (da)	2009-08-31
WO2002074784A3 (en)	2002-11-21
EP1243262B1 (en)	2006-05-31
FR09C0041I2 (pt)	2010-01-22
FR09C0041I1 (pt)	2009-10-30
US8053476B2 (en)	2011-11-08
DE122009000053I1 (de)	2010-05-27
ATE327744T1 (de)	2006-06-15
HK1058368A1 (en)	2004-05-14
ZA200300858B (en)	2003-07-09
EA200300932A1 (ru)	2004-04-29
AU2002257681C1 (en)	2008-02-21
CA2419397C (en)	2009-09-15
KR100773100B1 (ko)	2007-11-02
SI21170A (sl)	2003-10-31
ES2262567T3 (es)	2006-12-01
CY1109308T1 (el)	2012-01-25
CA2419397A1 (en)	2002-09-26
SI1373300T1 (sl)	2009-10-31
AU2002257681B2 (en)	2007-06-07
LU91590I2 (fr)	2009-10-05
IL154087A (en)	2010-05-17
CN101332292A (zh)	2008-12-31
CN100415225C (zh)	2008-09-03
HUP0303600A2 (hu)	2004-03-01
DE60120104T2 (de)	2006-09-21
DE60120104D1 (de)	2006-07-06
IL154087A0 (en)	2003-07-31
CZ20032763A3 (cs)	2004-01-14
CY2009013I1 (el)	2012-01-25
NO20033629L (no)	2003-08-15
CY1105533T1 (el)	2010-07-28
CN1498103A (zh)	2004-05-19
MXPA03008467A (es)	2003-12-08
ES2326627T3 (es)	2009-10-16
US20050085423A1 (en)	2005-04-21
EA007532B1 (ru)	2006-10-27
EP1373300A2 (en)	2004-01-02
AU2002257681A2 (en)	2002-10-03
DE60232407D1 (de)	2009-07-02
DK1243262T3 (da)	2006-10-02
BR0205823A (pt)	2003-10-21
US6803481B2 (en)	2004-10-12
NL300399I1 (en)	2009-10-01
HUP0303600A3 (en)	2011-11-28
PL362985A1 (en)	2004-11-15
JP2004524340A (ja)	2004-08-12
KR20040004369A (ko)	2004-01-13
US20030171300A1 (en)	2003-09-11
PT1373300E (pt)	2009-07-22
EP1373300B1 (en)	2009-05-20
US20070054962A1 (en)	2007-03-08
SK287539B6 (sk)	2011-01-04
PL216213B1 (pl)	2014-03-31
UA82645C2 (uk)	2008-05-12
NZ523865A (en)	2004-12-24
WO2002074784A2 (en)	2002-09-26
SK12832003A3 (sk)	2004-02-03
ATE431833T1 (de)	2009-06-15
NO20033629D0 (no)	2003-08-15
CN101332292B (zh)	2012-06-20
JP4955906B2 (ja)	2012-06-20
CY2009013I2 (el)	2012-01-25

Publication	Publication Date	Title
PT1243262E (pt)	2006-10-31	Nova utilizacao de uma classe de compostos peptideos para o tratamento da dor inflamatoria nao neuropatica
WO2002085342A3 (en)	2004-01-15	Use of nsaids for prevention and treatment of cellular abnormalities of the lung or bronchial pathway
EA200300933A1 (ru)	2004-04-29	Новое применение соединения из класса пептидов для лечения аллодинии или других различных типов хронической или фантомной боли
BR9701248A (pt)	1999-10-13	Novos pró-medicamentos para a terapia de tumores e distúrbios inflamatórios
PT1423391E (pt)	2006-09-29	Pirrolopirimidinas como agentes para a inibicao de proteases de cisteina
BR0313059B8 (pt)	2021-07-27	composto, e, composição farmacêutica
MX2008002293A (es)	2008-03-14	Uso novedoso de compuestos peptidicos para tratar dolor muscular.
BRPI0416268A (pt)	2007-12-11	composições de delta-9-thc e métodos para o tratamento de sintomas associados à esclerose múltipla
BRPI0411895A (pt)	2006-08-29	formulações para o tratamento de condições de artrite
CY1113651T1 (el)	2016-06-22	Αντιφλεγμονωδη σκευασματα
CL2007002387A1 (es)	2008-01-18	Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de artritis y dolor.
BR0212606A (pt)	2004-08-17	Combinação
NO20061302L (no)	2006-05-19	Derivater av hydroksaminsyre som metalloproteinseinbitorer
EA200700102A1 (ru)	2007-06-29	Лечение невропатической боли, фибромиалгии или ревматоидного артрита
BR9913526A (pt)	2001-06-05	Métodos de tratamento da osteoartrite com inibidores de sintase de óxido nìtrico induzìvel
PT1399142E (pt)	2006-10-31	Utilizacao de acetil-l-carnitina em associacao com biotina para o tratamento de doentes com diabetes mellitus insulino-resistente do tipo 2
FI20002525A0 (fi)	2000-11-17	Tulehduksenvastaisia aineita
BR0304636A (pt)	2005-06-28	Uso de composições para o tratamento de rosácea
CL2004001622A1 (es)	2005-06-03	Procedimiento para la transformacion esteroideos 3-ol-5-eno-7-sustituidos o 3-carboxi-5-eno-7-sustituidos en compuestos esterodeos 3-ceto-4-eno-7-sustituidos, donde la bacteria es un miembro del genero flavobacterium.